Diiodohydroxyquinoline - CAS 83-73-8
| Catalog: |
BB037083 |
| Product Name: |
Diiodohydroxyquinoline |
| CAS: |
83-73-8 |
| Synonyms: |
iodoquinol;83-73-8;Diiodohydroxyquinoline;5,7-diiodoquinolin-8-ol;5,7-Diiodo-8-hydroxyquinoline;5,7-Diiodo-8-quinolinol;Diiodoquin;Diodoquin;Yodoxin;DIIODOHYDROXYQUIN;Lanodoxin;Searlequin;Zoaquin;Ioquin;Quinadome;Sebaquin;8-Quinolinol, 5,7-diiodo-;Diodohydroxyquin;Dijodoxichinoline;Enterodiamoebin;Diamoebin;Dinoleine;Diodoquine;Diodoxylin;Direxiode;Disoquin;Embequin;Enterosept;Floraquin;Fluoraquin;Moebiquin;Dyodin;Di-quinol;Stanquinate;Rafamebin;5,7-Diiodo-oxine;Ioquin suspension;Dijodoxichinolinum;8-Hydroxy-5,7-diiodoquinoline;5,7-Diodo-8-quinolinol;Diodoxyquinoleine;Diiodoidrossichinolina;Panaquin;Diiodohidroxiquinoleina;Diiodohydroxyquinoleine;Diiodohydroxyquinolinum;SS 578;Enterodiamoebine;NSC 8704;NSC-8704;5,7-Diiod-8-chinolinol [IUPAC];Diiodohydroxyquinoline [INN];MLS000069404;CHEBI:5950;DTXSID6023155;63W7IE88K8;MMV002817;SS-578;NCGC00018098-04;SMR000059090;C9H5I2NO;Diiodohydroxyquinoline (INN);Iodoquinol [USAN];DTXCID003155;Caswell No. 354;Iodoquinol;5,7-Diiodo-8-hydroxyquinoline;5,7-Diiodo-8-quinolinol;CAS-83-73-8;Diiodoidrossichinolina [DCIT];HSDB 3224;SR-01000002969;Diiodohydroxyquinolinum [INN-Latin];Iodoquinol [USAN:USP];Diiodohydroxyquinoleine [INN-French];EINECS 201-497-9;5,7-Diiod-8-chinolinol;Diiodohidroxiquinoleina [INN-Spanish];EPA Pesticide Chemical Code 024003;BRN 0153639;Searlewuin;Meobiquin;UNII-63W7IE88K8;AI3-16443;5,7-Diiodooxine;component of Vytone;Iodoquinol (USP);Yodoxin (TN);MFCD00006789;Spectrum_000943;IODOQUINOL [MI];8-Quinolinol,7-diiodo-;Spectrum2_001041;Spectrum3_000470;Spectrum4_000020;Spectrum5_000872;IODOQUINOL [HSDB];4,7-Diiodo-8-quinolinol;bmse000836;EC 201-497-9;cid_3728;SCHEMBL3460;IODOQUINOL [USP-RS];BSPBio_002180;CBDivE_011080;KBioGR_000399;KBioSS_001423;ksc-8-193;CHEMBL86754;DivK1c_000119;SPECTRUM1500353;SPBio_000962;DI-IODOHYDROXY QUINOLINE;5,7-bis(iodanyl)quinolin-8-ol;BDBM66035;HMS500F21;KBio1_000119;KBio2_001423;KBio2_003991;KBio2_006559;KBio3_001400;UXZFQZANDVDGMM-UHFFFAOYSA-;IODOQUINOL [USP IMPURITY];NSC8704;NINDS_000119;WLN: T66 BNJ GI II JQ;HMS1920H05;HMS2091N15;HMS2230G24;HMS3369C20;IODOQUINOL [USP MONOGRAPH];KUC105860N;Pharmakon1600-01500353;HY-B1400;Tox21_110823;CCG-40132;NSC757077;s4565;STK070581;DIIODOHYDROXYQUINOLINE [MART.];AKOS000120804;Tox21_110823_1;5,7-Diiodo-8-hydroxyquinoline, 97%;CS-4910;DB09115;DIIODOHYDROXYQUINOLINE [WHO-DD];Iodoquinol (5,7-Diiodoquinolin-8-ol);NSC-757077;IDI1_000119;NCGC00018098-01;NCGC00018098-02;NCGC00018098-03;NCGC00018098-05;NCGC00018098-07;NCGC00018098-08;NCGC00021685-03;NCGC00021685-04;DS-17759;SBI-0051417.P003;DB-056739;AM20061527;D1736;NS00003663;EN300-18288;C07636;D00581;F12461;AB00052024_12;AN-329/13210059;Q5276473;SR-01000002969-2;SR-01000002969-5;BRD-K75855670-001-06-8;BRD-K75855670-001-14-2;Z57825347;F3034-0058;Iodoquinol, United States Pharmacopeia (USP) Reference Standard;InChI=1/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H; |
| Application: |
5,7-Diiodo-8-Quinolinol is active against both cyst and trophozoites that are localized in the lumen of the intestine. It is used in the treatment of amoebiasis. It is considered the drug of choice for treating asymptomatic or moderate forms of amebiasis. |
| IUPAC Name: | 5,7-diiodoquinolin-8-ol |
| Description: | 5,7-Diiodo-8-Quinolinol is a topical therapeutic agent with satisfactory antibacterial properties. It is poorly absorbed from the gastrointestinal tract and is used as a luminal amebicide. It acts by chelation of ferrous ions essential for metabolism. It is active against both cyst and trophozoites that are localized in the lumen of the intestine. It is used in the treatment of amoebiasis. It is considered the drug of choice for treating asymptomatic or moderate forms of amebiasis. It was discovered by Adco Co. |
| Molecular Weight: | 530.5 |
| Molecular Formula: | C26H26O12 |
| Canonical SMILES: | COC(=O)[C@@]1(C[C@H]([C@H]([C@@H](C1)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)OC(=O)/C=C/C3=CC(=C(C=C3)O)O)O)O |
| InChI: | InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H |
| InChI Key: | UXZFQZANDVDGMM-UHFFFAOYSA-N |
| Boiling Point: | 401.8±45.0 °C | Condition: Press: 760 Torr |
| Melting Point: | 210 °C |
| Purity: | 98 % |
| Density: | 2.491±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr |
| Solubility: | 10 mM in DMSO |
| Appearance: | Yellow to tan powder or crystals |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |
| MDL: | MFCD00006789 |
| LogP: | 3.14960 |
| Quality Standard: | USP standard |
| Stability: | Stable in air |
| GHS Hazard Statement: | H302 (98.46%): Harmful if swallowed [Warning Acute toxicity, oral] |
| Precautionary Statement: | P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P310, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501 |
| Signal Word: | Danger |
| Publication Number | Title | Priority Date |
|---|
| CN-113292492-A | Method for preparing clioquinol and diiodoquinol by one-pot method | 20210610 |
| WO-2021207801-A1 | Immune cells with enhanced function | 20200417 |
| US-2021322447-A1 | Transdermal micro-dosing delivery of psychedelics derivatives | 20200416 |
| WO-2021209815-A1 | Transdermal micro-dosing delivery of psychedelics derivatives | 20200416 |
| KR-20200043944-A | Bioactive substance deleviry carrier | 20200413 |
| PMID | Publication Date | Title | Journal |
|---|
| 32473310 | 20200901 | Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system | Pharmacological research |
| 23769903 | 20130905 | FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1 | Chemico-biological interactions |
| 23571415 | 20130601 | Structure-based identification of OATP1B1/3 inhibitors | Molecular pharmacology |
| 22382561 | 20120101 | Pleural empyema secondary to rupture of amoebic liver abscess | Internal medicine (Tokyo, Japan) |
| 22577371 | 20120101 | Double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba | Dermatology research and practice |
| Complexity: | 191 |
| Compound Is Canonicalized: | Yes |
| Covalently-Bonded Unit Count: | 1 |
| Defined Atom Stereocenter Count: | 0 |
| Defined Bond Stereocenter Count: | 0 |
| Exact Mass: | 396.84606 |
| Formal Charge: | 0 |
| Heavy Atom Count: | 13 |
| Hydrogen Bond Acceptor Count: | 2 |
| Hydrogen Bond Donor Count: | 1 |
| Isotope Atom Count: | 0 |
| Monoisotopic Mass: | 396.84606 |
| Rotatable Bond Count: | 0 |
| Topological Polar Surface Area: | 33.1 Å2 |
| Undefined Atom Stereocenter Count: | 0 |
| Undefined Bond Stereocenter Count: | 0 |
| XLogP3: | 3.1 |
-
Catalog: BB033560
(2,8-Bis-trifluoromethyl-quinolin-4-yl)-pyridin-2-yl-methanol
Detail
-
Catalog: BB023177
(Phenyl)(3-quinolyl)methanol
Detail
-
Catalog: BB043168
(+/-)-3-Amino-1,2,3,4-tetrahydroquinoline
Detail
-
Catalog: BB010386
(RS)-1-(2-Diphenylphosphino-1-naphthyl)isoquinoline
Detail
-
Catalog: BB004090
(3-Pyridyl)(3-quinolyl)methanol
Detail
-
Catalog: BB053504
(Isoquinolin-5-yl)methanamine
Detail
-
Catalog: BB009832
(2-Amino-5,6,7,8-tetrahydro-3-quinolyl)(phenyl)methanone
Detail
-
Catalog: BB032144
(R)-2-Methyl-1,2,3,4-tetrahydroquinoline
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Quinoline/Isoquinoline
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS
